111 related articles for article (PubMed ID: 21934542)
1. What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use?
Ballinger JR; Solanki KK
Nucl Med Commun; 2011 Dec; 32(12):1109-12. PubMed ID: 21934542
[No Abstract] [Full Text] [Related]
2. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
3. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors?
Öberg K
Endocrine; 2012 Aug; 42(1):3-4. PubMed ID: 22562721
[No Abstract] [Full Text] [Related]
4. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
5. Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with ⁶⁸Ga-labelled somatostatin analogues: could this be tailored according to specific clinical context and individual patient requirement?
Basu S
Nucl Med Commun; 2012 Oct; 33(10):1007-10. PubMed ID: 22850607
[No Abstract] [Full Text] [Related]
6. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of
Ortiz S; García JR; Riera E; Soler M; Compte Montañez A; Valls E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):244-245. PubMed ID: 32089469
[No Abstract] [Full Text] [Related]
8. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides?
Sharma P; Mukherjee A; Bal C; Malhotra A; Kumar R
AJR Am J Roentgenol; 2013 Dec; 201(6):1340-7. PubMed ID: 24896203
[TBL] [Abstract][Full Text] [Related]
9. Should we stop offering indium-111 octreotide scans in favour of gallium-68 PET-CT scans in the UK?
Kalsy N; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1221-1222. PubMed ID: 27612035
[No Abstract] [Full Text] [Related]
10. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
Smith DL; Breeman WA; Sims-Mourtada J
Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of Gallium-68.
Banerjee SR; Pomper MG
Appl Radiat Isot; 2013 Jun; 76():2-13. PubMed ID: 23522791
[TBL] [Abstract][Full Text] [Related]
12. Cancer with unknown primary: finding a needle in a hay stack.
Giesel FL; Mehndiratta A; Mafomane MP; Zechmann CM; Bergmann F; Schemmer P; Haberkorn U; Kratochwil C
Exp Oncol; 2012; 34(1):64-5. PubMed ID: 22453152
[TBL] [Abstract][Full Text] [Related]
13. PET/CT with 68Gallium-DOTA-peptides in NET: an overview.
Ambrosini V; Campana D; Tomassetti P; Grassetto G; Rubello D; Fanti S
Eur J Radiol; 2011 Nov; 80(2):e116-9. PubMed ID: 20800401
[TBL] [Abstract][Full Text] [Related]
14. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
15. Myocardial metastases from neuroendocrine tumors: incidence and relevance.
Kwekkeboom DJ
Endocrine; 2014 Sep; 47(1):5-6. PubMed ID: 24965229
[No Abstract] [Full Text] [Related]
16. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides.
Schultz MK; Mueller D; Baum RP; Leonard Watkins G; Breeman WA
Appl Radiat Isot; 2013 Jun; 76():46-54. PubMed ID: 23026223
[TBL] [Abstract][Full Text] [Related]
17. [68Ga-DOTA-PET for neuroendocrine tumours].
Loimaala A; Mäenpää H; Lipponen T; Schildt J; Kämäräinen EL; Karhumäki L; Ahonen A
Duodecim; 2014; 130(19):1931-8. PubMed ID: 25558614
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
19. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
20. High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT.
Kulkarni HR; Prasad V; Kaemmerer D; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():373-8. PubMed ID: 22918769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
